Perricone et al. suggested that a cut-off of ≥0.8% JAK2 V617F allele burden is very indicative for the presence of MPN and that monitoring the JAK2 mutation burden over time is a convenient way to assess clonal hematopoiesis expansion [7]. Here, JAK2 is linked to myeloproliferative neoplasm.